Proactive Investors - Run By Investors For Investors

Renovo ends Adaprev development

Renovo ends Adaprev development

Renovo (LON:RNVO) told investors that it has decided to cease further development of its Adaprev product.

It reported its safety trial reports today. The patients were assessed 26 weeks after receiving surgery to repair flexor tendons in the hand. Adaprev was designed to prevent and reduce scarring after tendon surgery.

The group said that safety measures of the Adaprev treated patients were similar to the patients in the standard care groups. 

Analysis of performance measures showed that patients treated with Adaprev had less range of motion than those in the standard care group.

Renovo said that the active range of motion was lower by an estimated 16.8 per cent in the Adaprev group than in the Standard Care group. The results had considerable variability, it added. 

“This first clinical trial of Adaprev showed that it was safe and well tolerated but did not produce encouraging preliminary performance data,” Renovo said.

“Accordingly the Board of Renovo have decided that no further development of, or expenditure on, Adaprev will occur.”

These results follow what the company describe as ‘surprising and disappointing’ results from a clinical trial for what was its lead product. 

In February Renovo revealed that it scar treatment, Juvista, failed to meet any of the clinical endpoints.

Renovo’s focus since then has been on cash preservation. Subsequently Renovo has scaled back its operation. It has closed it labs and it contracted drug development work has continued on an outsourced basis.

The firm has one more clinical trial that is still underway. A fully recruited proof of concept clinical trial for its Prevascar drug is expected to report data in the first half of next year.

This morning Renovo also revealed its financial results for the twelve months ended September 30.

At the end of the period the group had a net cash position including cash equivalents and investments of £36.4 million.

"Following the surprising and disappointing results during the year, the Group has been completely reorganised and is looking to maximise shareholder value,” said chairman Professor Mark Ferguson.

 “The Group's focus remains on minimising cash outflow and limiting expenditure to the ongoing trial of Prevascar and other value realisation programmes only.

“The Board is considering all options to maximise value including acquisitions and mergers of external companies.”

View full RNVO profile View Profile

Renovo Group Plc Timeline

December 13 2012
April 16 2012
December 15 2011
November 18 2011

Related Articles

lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use